2023
Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States
Desai N, Sutton M, Xie J, Fine J, Gao W, Owens A, Naidu S. Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States. The American Journal Of Cardiology 2023, 192: 16-23. PMID: 36709525, DOI: 10.1016/j.amjcard.2022.12.030.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyIndex dateCardiovascular eventsIncidence rateSymptomatic obstructive hypertrophic cardiomyopathyAtrial fibrillation/flutterCommon cardiovascular eventMonths continuous eligibilityHealthcare resource utilizationMedicare Supplemental databasesIBM MarketScan CommercialEligible patientsDiagnosis dateMarketScan CommercialClinical outcomesContinuous eligibilityTreatment optionsCumulative riskPatientsResource utilizationPharmacotherapyCardiomyopathyDisease
2020
Outpatient Cost-effectiveness Study of Hyperkalemia Management
Desai N, Rowan C, Alvarez P, Fogli J, Coca S. Outpatient Cost-effectiveness Study of Hyperkalemia Management. Journal Of Cardiac Failure 2020, 26: s115. DOI: 10.1016/j.cardfail.2020.09.332.Peer-Reviewed Original ResearchOutpatient costsOptum's de-identified ClinformaticsEnd-stage renal diseaseMatched-cohort designData Mart DatabaseTreatment of hyperkalemiaMedicare Advantage populationCost-effectiveness studiesReal-world evidenceMEq/LCongestive HFHK cohortHyperkalemia managementPotassium bindersIndex dateCohort studyRenal diseaseOutpatient outcomesMean ageBaseline variablesInclusion criteriaPatiromerLarge cohortStudy populationCensoring event
2019
Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
Desai N, Rowan C, Alvarez P, Fogli J, Toto R. Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients. Journal Of Drug Assessment 2019, 8: 2-2. PMCID: PMC6764378, DOI: 10.1080/21556660.2019.1658287.Peer-Reviewed Original ResearchContinuous exposureRenin angiotensin aldosterone system inhibitor therapyAldosterone system inhibitor therapyDevelopment of hyperkalemiaCornerstone of therapyRetrospective cohort studyOptum Clinformatics DataMartMEq/LNational Health InsuranceBinder therapyHK cohortHyperkalemia treatmentPotassium bindersRAASi therapyIndex dateCohort studyInhibitor therapyContinuation ratesMean ageDiagnosis codesITT groupCardiovascular diseaseClinformatics DataMartMedicare patientsPatiromer